ARS PHARMACEUTICALS INC. - COMMON STOCK

neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)

29 Dec 2025 08:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

26 Nov 2025 08:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

10 Nov 2025 06:00:00 By Nasdaq GlobeNewswire

ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)

04 Nov 2025 08:00:02 By Nasdaq GlobeNewswire

UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

03 Nov 2025 14:23:30 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results

03 Nov 2025 08:00:00 By Nasdaq GlobeNewswire

ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

03 Nov 2025 07:45:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)

08 Oct 2025 08:00:01 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®

29 Sep 2025 16:05:00 By Nasdaq GlobeNewswire

neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

19 Sep 2025 08:00:26 By Nasdaq GlobeNewswire

Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis

08 Sep 2025 08:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

28 Aug 2025 08:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)

13 Aug 2025 07:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results

04 Aug 2025 08:00:00 By Nasdaq GlobeNewswire

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

18 Jul 2025 09:25:25 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

27 May 2025 08:00:44 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

14 May 2025 07:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

07 May 2025 08:00:01 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

05 May 2025 08:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

02 May 2025 08:00:00 By Nasdaq GlobeNewswire